Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.In this 24-week, multicenter, randomized, do...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3988010?pdf=render |
| _version_ | 1828375678575181824 |
|---|---|
| author | Sin Gon Kim Doo Man Kim Jeong-Taek Woo Hak Chul Jang Choon Hee Chung Kyung Soo Ko Jeong Hyun Park Yong Soo Park Sang Jin Kim Dong Seop Choi |
| author_facet | Sin Gon Kim Doo Man Kim Jeong-Taek Woo Hak Chul Jang Choon Hee Chung Kyung Soo Ko Jeong Hyun Park Yong Soo Park Sang Jin Kim Dong Seop Choi |
| author_sort | Sin Gon Kim |
| collection | DOAJ |
| description | The aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.In this 24-week, multicenter, randomized, double-blind, parallel-group, placebo controlled study, 173 patients were randomly assigned (a 2∶1 ratio) to lobeglitazone 0.5 mg (n=115) or matching placebo (n=58) orally once daily. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to the end of treatment. The secondary endpoints included various glycemic parameters, lipid parameters and safety profile (ClinicalTrials.gov number NCT01001611).At 24 weeks, a significant reduction in HbA1c was observed with lobeglitazone versus placebo (-0.44% vs 0.16%, mean difference -0.6%, p<0.0001). The goal of HbA1c <7% was achieved significantly more in the lobeglitazone group compared to the placebo group (44% vs 12%, p<0.0001). Markers of insulin resistance were also improved in the lobeglitazone group. In addition, lobeglitazone treatment significantly improved triglycerides, high density lipoprotein cholesterol, small dense low density lipoprotein cholesterol, free fatty acid, and apolipoprotein-B/CIII compared to placebo (p<0.01, respectively). More weight gain was observed in the lobeglitazone group than the placebo group (0.89 kg vs - 0.63 kg, mean difference 1.52 kg, p<0.0001). The safety profile was comparable between the two groups and lobeglitazone was well tolerated.Lobeglitazone 0.5 mg showed a favorable balance in the efficacy and safety profile. The results support a potential role of lobeglitazone in treating type 2 diabetes.Clinicaltrials.gov NCT01001611. |
| first_indexed | 2024-04-14T07:50:20Z |
| format | Article |
| id | doaj.art-6461739a6c9d46c9810aff861cd283c7 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T07:50:20Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-6461739a6c9d46c9810aff861cd283c72022-12-22T02:05:13ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0194e9284310.1371/journal.pone.0092843Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.Sin Gon KimDoo Man KimJeong-Taek WooHak Chul JangChoon Hee ChungKyung Soo KoJeong Hyun ParkYong Soo ParkSang Jin KimDong Seop ChoiThe aim of this study was to assess the glucose-lowering and lipid-modifying effects, and safety profile of lobeglitazone, a novel peroxisome proliferator-activated receptor- γ agonist, compared to placebo as a monotherapy in patients with type 2 diabetes.In this 24-week, multicenter, randomized, double-blind, parallel-group, placebo controlled study, 173 patients were randomly assigned (a 2∶1 ratio) to lobeglitazone 0.5 mg (n=115) or matching placebo (n=58) orally once daily. The primary endpoint was the change in glycated hemoglobin (HbA1c) from baseline to the end of treatment. The secondary endpoints included various glycemic parameters, lipid parameters and safety profile (ClinicalTrials.gov number NCT01001611).At 24 weeks, a significant reduction in HbA1c was observed with lobeglitazone versus placebo (-0.44% vs 0.16%, mean difference -0.6%, p<0.0001). The goal of HbA1c <7% was achieved significantly more in the lobeglitazone group compared to the placebo group (44% vs 12%, p<0.0001). Markers of insulin resistance were also improved in the lobeglitazone group. In addition, lobeglitazone treatment significantly improved triglycerides, high density lipoprotein cholesterol, small dense low density lipoprotein cholesterol, free fatty acid, and apolipoprotein-B/CIII compared to placebo (p<0.01, respectively). More weight gain was observed in the lobeglitazone group than the placebo group (0.89 kg vs - 0.63 kg, mean difference 1.52 kg, p<0.0001). The safety profile was comparable between the two groups and lobeglitazone was well tolerated.Lobeglitazone 0.5 mg showed a favorable balance in the efficacy and safety profile. The results support a potential role of lobeglitazone in treating type 2 diabetes.Clinicaltrials.gov NCT01001611.http://europepmc.org/articles/PMC3988010?pdf=render |
| spellingShingle | Sin Gon Kim Doo Man Kim Jeong-Taek Woo Hak Chul Jang Choon Hee Chung Kyung Soo Ko Jeong Hyun Park Yong Soo Park Sang Jin Kim Dong Seop Choi Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS ONE |
| title | Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. |
| title_full | Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. |
| title_fullStr | Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. |
| title_full_unstemmed | Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. |
| title_short | Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. |
| title_sort | efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24 weeks a multicenter randomized double blind parallel group placebo controlled trial |
| url | http://europepmc.org/articles/PMC3988010?pdf=render |
| work_keys_str_mv | AT singonkim efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT doomankim efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT jeongtaekwoo efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT hakchuljang efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT choonheechung efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT kyungsooko efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT jeonghyunpark efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT yongsoopark efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT sangjinkim efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial AT dongseopchoi efficacyandsafetyoflobeglitazonemonotherapyinpatientswithtype2diabetesmellitusover24weeksamulticenterrandomizeddoubleblindparallelgroupplacebocontrolledtrial |